Subscribe to Email Alerts
Menu
About Us
About INOVIQ
Market Opportunity
Board
Management
Medical & Scientific Advisory Board
Partners
Compliance
Careers
Technology
Our Science
NETs Platform
SubB2M Platform
BARD1 Biomarker Technology
hTERT ICC Assay
Intellectual Property
Publications
Resources
Business Development
Products
Our Products
EXO-NET® Pan-Exosome
Product Overview
Technical Information
Data & Figures
Ordering
hTERT ICC Test
Pipeline
Development Pipeline
EXO-Ovarian Cancer Test
Exosome Therapeutics
NeuCA15-3 Test
Investors
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
News & Events
INOVIQ in the News
Conferences & Events
Contact
Contact Us
Subscribe to Email Alerts
Analyst Reports
Heading &
Sub-heading can be edited through HQI
Investors
>
Analyst Reports
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
Analyst Reports
Filter by Year:
2026
2025
2024
2023
2022
17-Dec-2024
MST Access Report | CAR-NK-exosome in-vitro proof of concept for breast cancer
6-Dec-2024
MST Access Report | Ovarian cancer biomarker validation
27-Aug-2024
MST Access Report | FY24: Solid Progress; Exosome Therapeutics Key Program to Watch
21-Aug-2024
MST Access Report | NEURO-NET validated for Parkinson's Disease EV isolation
9-Aug-2024
MST Access Report | Ready to Fund Key FY25 Priorities
5-Jun-2024
MST Access Report | Engineered Exosomes Kill Breast Cancer Cells In-vitro
7-May-2024
MST Access Report | Leveraging Exosome Advantage
28-Feb-2024
MST Access Report | SubB2M/CA15-3 test: beats leading breast cancer test by 19%
1
